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Dedicator of cytokinesis 8 (DOCK8) deficiency is an autosomal recessive, combined 
immunodeficiency within the spectrum of hyper-IgE syndromes. Epstein–Barr virus- 
positive lymphomatoid granulomatosis (LYG) (EBV +  LYG) is a rare diagnosis and a 
previously unreported presentation of DOCK8 deficiency. A 10-year-old girl was initially 
evaluated for mild eczema and recurrent sinopulmonary infections. She had normal 
immunoglobulins with elevated IgE, poor polysaccharide response with low switched 
memory B cells, low CD4 count, and normal mitogen and antigen responses. Despite 
clinical improvement following immunoglobulin replacement, a prolonged cough 
prompted a CT scan, which showed nodules. Biopsy identified a Grade 2 EBV + LYG. 
Due to an inadequate response with chemotherapy, further workup for primary immu-
nodeficiency was performed. With her symptoms of eczema and IgE elevation, along 
with her brother’s history of recurrent sinopulmonary infections and warts, targeted 
sequencing of DOCK8 was performed revealing compound heterozygous mutations for 
the two siblings. Both patients were successfully transplanted with resolution of the LYG 
and warts, respectively. This is the first reported case of LYG in DOCK8 deficiency. The 
EBV-driven lymphoproliferative disease along with the infection history in the brother led 
to the diagnosis of DOCK8 deficiency and curative hematopoietic stem cell transplants.
Keywords: DoCK8, lymphomatoid granulomatosis, lymphomatous granulomatosis, eBV lymphoproliferation, 
bone marrow transplantation
BaCKGRoUND
Dedicator of cytokinesis 8 (DOCK8) deficiency is a combined immunodeficiency, which was initially 
described as an autosomal recessive hyper IgE immunodeficiency syndrome (AR-HIES) (1). Unlike 
the more common autosomal dominant hyper-IgE syndromes (HIES) caused by loss of function 
mutations in STAT3, DOCK8 deficiency lacks the osseous and connective tissue defects that are 
prominent within the described phenotype of AD-HIES. Instead, patients with DOCK8 deficiency 
have increased risk of specific viral, bacterial, and fungal infections as well as prominent allergies and 
malignancies (1–3). Typically, DOCK8 deficiency is associated with significant cutaneous manifesta-
tions including disseminated HPV, molluscum contagiosum, recurrent herpes and varicella zoster. 
FIGURe 2 | pathology of the lung biopsy of the right lower lobe 
consistent with lymphomatoid granulomatosis. (a) 2× image showing 
large areas of necrosis. (B) 20× image showing lymphohistiocytic infiltrate 
with some large atypical lymphoid cells. (C) 40× image showing CD20 
positive B lymphocytes by immunostaining. (D) 10× EBER showing EBV 
positive cells, including those in the vessel wall (arrow).
FIGURe 1 | (a) Chest CT prior to hematopoietic stem cell transplant for 
patient 1 showing multiple masses due to EBV lymphoproliferative disease. 
(B) Multiple warts on the knee for patient 2.
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Malignancy is frequent in DOCK8 deficiency, predominantly, 
lymphoma and squamous cell carcinomas, and often leads to 
early mortality. In a large series of patients, mortality was over 
50% by age 20 years (2).
Due to the high rates of morbidity and mortality, hematopoi-
etic stem cell transplant (HSCT) is the treatment of choice and 
leads to resolution of many of the disease complications (4, 5). 
However, due to the multiple and variable initial presentations, 
DOCK8 deficiency may go undiagnosed for many years, leading 
to increased end organ damage. We present two siblings with 
DOCK8 deficiency identified initially through presentation of 
EBV+ lymphomatoid granulomatosis (LYG) in the lung in the 
younger sibling, a previously unreported association.
Case RepoRt
Case #1
A 10-year-old girl first presented with an isolated third cranial 
nerve palsy associated with pansinusitis. She had a history of 
allergic rhinitis, mild atopic dermatitis, and a remote history of 
recurrent otitis media. There were no associated skin infections, 
bone abnormalities, or tooth retention. Laboratory examination 
revealed an IgE of 4,430 IU/mL with sensitizations to dust mites 
and Candida. Over the next few years, the patient developed 
recurrent sinopulmonary infections leading to further immu-
nologic evaluation including normal IgG, normal IgA, slightly 
low IgM, and elevated IgE levels. Pneumococcal antibodies were 
protective in only 1/14 serotypes with low switched memory 
B cells; she responded poorly to both pure bacterial as well as con-
jugated polysaccharide vaccinations. Lymphocyte subpopulations 
showed low CD4 levels (absolute number 410), but mitogen and 
antigen testing were normal. She was diagnosed with a combined 
immune deficiency and started on monthly immune globulin 
replacement and trimethoprim/sulfamethoxazole prophylaxis. 
CT scan of the chest showed mild fusiform bronchiectasis in 
her lower left lobe. Sequencing of STAT3 for AD-HIES was wild 
type. For the next several years, she remained stable with few 
breakthrough infections.
At age 14, a persistent cough led to repeat CT scan, which 
showed two new areas of nodularity (1–2 cm) in her left lower 
lobe (Figure  1). Pulmonary function testing was normal. 
Bronchoscopy was unremarkable, but due to the nodular 
appearance, she was started on empiric antifungal therapy with 
voriconazole. Rapid enlargement of bilateral lesions led to wedge 
biopsy, showing EBV+ Grade 2 LYG (Figure 2). Given the rar-
ity of EBV + LYG and her age, she was referred to the National 
Cancer Institute for evaluation and treatment. Interferon alpha 
response to the LYG was minimal. Combination chemotherapy 
with etoposide, prednisone, vincristine, cyclophosphamide, 
doxorubicin, and rituximab (EPOCH-R) also elicited minimal 
response, and the LYG was thought to have evolved into a 
treatment-refractory lymphoma. In an attempt to explain poorly 
controlled EBV, eczema, and recurrent sinopulmonary infections 
with B cell failure, targeted genetic testing was done, which identi-
fied compound heterozygous mutations in DOCK8, c.1805G>A, 
p.W602X and c.4540delG, p.E1514KfsX8. Of note, she had mild 
atopic dermatitis, a small number of warts (flat and verrucous) 
and no history of molluscum. The patient and family gave written 
consent in accordance with the Declaration of Helsinki for an IRB 
approved clinical protocol for patients to receive bone marrow 
transplants (NCT01176006). She received a matched allogeneic 
stem cell transplant supplemented with donor-derived EBV-
specific cytotoxic T lymphocytes, with complete regression of her 
EBV-related malignancy [Patient#5 in Cuellar-Rodriguez et  al. 
(5)]. Three years after transplant, she has minimal sinopulmonary 
infections and normal IgG, IgM, and IgE with slightly low IgA 
levels. She sustains a robust response to repeat pneumococcal 
vaccination and her lymphocyte subpopulations have completely 
normalized.
Case #2
Case 1’s older brother had a history of recurrent pneumonias 
and at age 5  years developed an empyema requiring a chest 
tube. Evaluation at that time revealed normal IgG, IgA, and IgM 
but an elevated IgE at 2,834  IU/mL. Both pneumococcal and 
taBLe 1 | Immunologic laboratories for both patients prior to HsCt.
patient 1, 
15 years (prior 
to lymphomatoid 
granulomatosis 
therapy)
patient 2, 
18 years
Normal
CD3 cells/μL 997 1,734 615–2,348
CD4 cells/μL 220 356 334–1,565
CD4/CD62L/CD45RA 57 102–1,041
CD4/CD62L/CD45RA− 109 162–614
CD4/CD62L−/CD45RA+ 0 0–29
CD4/CD62L−/CD45RA− 188 42–225
CD8 cells/μL 471 1,264 149–853
CD8/CD62L/CD45RA 43 85–568
CD8/CD62L/CD45RA− 100 25–180
CD8/CD62L−/CD45RA+ 227 11–172
CD8/CD62L−/CD45RA− 894 24–175
CD19 cell/μL 416 270 59–329
CD19/CD27 0.4% 0.6% 5–18%
NK cells/μL 405 268 109–607
IgG mg/dL 1,240a 2,070 716–1,711
IgA mg/dL 103 176 47–249
IgM mg/dL <21 67 15–188
IgE (IU/mL) 1,890b 4,223 0–90
aOn IgG replacement therapy.
bIgE was evaluated at 10 years.
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H. influenzae B titers were low but he responded well to booster 
vaccinations. He was treated symptomatically for atopic disease 
(including conjunctivitis, rhinitis, and atopic dermatitis). His 
atopy continued and he was treated for multiple skin and soft 
tissue infectious in the setting of his atopic dermatitis, which 
was mildly responsive to corticosteroid treatment. Examination 
at age of 17 years found widespread warts on his elbows, knees, 
and the nape of his neck (Figure 1) and, during evaluation, he 
reported ongoing onychomycosis. Immunologic evaluation at 
that time showed normal IgG, IgA, and IgM with an elevated IgE 
of 4,368  IU/mL. There was low protection in response to both 
pneumococcal and tetanus vaccines, low switched memory B 
cells, and a low CD4+ T cell count (absolute number 385/μL) 
(Table 1). He had intermittent low grade EBV viremia and his 
pulmonary imaging was only remarkable for reactive lymph 
nodes in the axilla and retroperitoneal areas. In view of his sister’s 
diagnosis, at age 20 years, he was tested and found to have the 
same compound heterozygous DOCK8 mutations. After diagno-
sis, he was placed on antibiotic prophylaxis with trimethoprim/
sulfamethoxazole until he successfully received a haploidentical 
HSCT on the same clinical trial of transplantation for patients 
with DOCK8 deficiency. He had a fairly unremarkable transplant 
course, and at 18  months posttransplant, the majority of his 
warts have resolved. Both parents were found to be heterozygous 
asymptomatic DOCK8 mutation carriers.
DIsCUssIoN
Mutations in DOCK8 were described as the cause of many cases 
of autosomal recessive hyper IgE syndrome in 2009 (1). DOCK8 
is one of the DOCK180 family of exchange factors, which are 
responsible for activating Rho-family GTPases such as RAC and 
CDC42, and play crucial roles in cell division, survival, adhesion, 
migration, activation and differentiation (6). DOCK8 protein is 
expressed primarily in lymphocytes; its absence results in a com-
bined immunodeficiency, characterized by impaired lymphocyte 
survival, migration and synapse formation (7–9). The increase in 
skin viral infections appears to be due to cytoskeletal defects that 
impair migration through the skin matrix (10), while the elevated 
rate of EBV infection and lymphoma likely relates to the poor NK 
function.
DOCK8 deficiency differs from dominant negative STAT3 
mutation because of the lack of connective tissue and skeletal 
abnormalities, with an increase in atopy and cutaneous viral 
infections. Although there is an increase in malignancy in STAT3 
deficiency, the incidence of malignancy and early mortality in 
DOCK8 deficiency is much higher, with early onset of lympho-
mas (both EBV+ and EBV−) and HPV+ squamous cell carcino-
mas (1–3). Case 1 had early EBV+ lymphoproliferative disease 
presenting as LYG, a novel manifestation. She further differed 
from most DOCK8-deficient patients by having only minimal 
atopic dermatitis and viral skin infections. Her brother’s history 
was more typical, with increased cutaneous viral infections and 
atopic dermatitis, despite minimal sinopulmonary infections in 
later childhood.
Although EBV+ and EBV− lymphomas have been reported 
in DOCK8 deficiency, this is the first report of LYG, a rare EBV+ 
lymphoproliferative disease, which almost always affects the 
lungs. Like in our patient, it typically presents with pulmonary 
nodules (11). Disease is most common between the fourth and 
sixth decades with a male predominance, but earlier presenta-
tions are being increasingly recognized. Some level of immune 
dysregulation is thought to predispose to the poor EBV control 
leading to LYG, and some patients have had prior autoimmun-
ity or immunodeficiency. Diagnosis is often delayed due to the 
predominantly pulmonary presentation, which is somewhat 
unusual for a lymphoproliferative process. Treatment is often 
aimed at augmenting the immune response, as was done in our 
patient with IFN alpha therapy, but there can be progression to 
lymphoma, as was noted in our patient. Although immunodefi-
ciency is infrequently identified in patients with LYG, the early 
age of onset and poor response to therapy in Case 1 argued in 
its favor.
These siblings illustrate key features of DOCK8 deficiency, 
including the phenotypic variation regarding atopy, sinopulmo-
nary infections, and cutaneous viral infections. In part, this may 
relate to reversion mutations with possible somatic mosaicism 
within certain cell lineages; however, this likely is not the only 
explanation. Although the reversion mutations may improve the 
disease progression, ultimate outcomes are similar to patients 
without reversions, so HSCT still should be the treatment of 
choice (12). Indeed, despite the reversion mutations found 
in both of our patients [patients #14 and 15 in Jing et al. (12), 
with #15 being the patient with LYG], the EBV lympholiferative 
disease still progressed, necessitating transplant for ultimate cure. 
These cases also highlight a novel manifestation of malignancy 
in DOCK8 deficiency and the benefit to early diagnosis and 
bone marrow transplant. Our index patient failed the typical 
therapy for EBV + LYG, leading to the consideration of a primary 
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immunodeficiency and a personalized transplant plan. Despite 
the conventional approach to allogeneic HSCT in lymphoma, 
where it is ideal for patients to be chemoresponsive or in remission 
prior to transplant, she had active disease during the transplant 
conditioning regimen and her tumors regressed only after HSCT.
Although children with DOCK8 deficiency may do well for 
years, the disease is associated with significant morbidity and 
early mortality, regardless of the severity of skin involvement 
or immunoglobulin derangement. Curative HSCT should be 
considered early in the course of DOCK8 deficiency, and active 
EBV lymphoproliferative disease should not prevent patients 
from being considered for transplant.
etHICs stateMeNt
This study was carried out in accordance with the recommenda-
tions of NIAID and NCI IRBs at the NIH with written informed 
consent from all subjects. All subjects gave written informed 
consent in accordance with the Declaration of Helsinki. The 
protocols were approved by the NIAID and NCI IRBs.
aUtHoR CoNtRIBUtIoNs
VRD, VD, AF wrote the primary manuscript, were involved in the 
management of the patients, and conceived of the case report. SP 
was the pathologist who took the pictures and wrote the descrip-
tions of the pathology figure. HS and her lab did the sequencing 
of the relevant gene to determine the diagnosis of the patients, 
and edited the paper. WW, KD, SH, and NS were involved in the 
clinical management and edited the manuscript.
aCKNoWLeDGMeNts
The content of this publication does not necessarily reflect the 
views or policies of the Department of Health and Human 
Services nor does mention of trade names, commercial products, 
or organizations imply endorsement by the U.S. Government. 
This research was supported (in part) by the Intramural Research 
Programs of the NIH, National Cancer Institute, Center for 
Cancer Research, and of the National Institute of Allergy and 
Infectious Diseases.
ReFeReNCes
1. Zhang Q, Davis JC, Lamborn IT, Freeman AF, Jing H, Favreau AJ, et  al. 
Combined immunodeficiency associated with DOCK8 mutations. N Engl 
J Med (2009) 361:2046–55. doi:10.1056/NEJMoa0905506 
2. Aydin SE, Kilic SS, Aytekin C, Kumar A, Porras O, Kainulainen L, et  al.  
DOCK8 deficiency: clinical and immunological phenotype and treatment 
options – a review of 136 patients. J Clin Immunol (2015) 35:189–98. 
doi:10.1007/s10875-014-0126-0 
3. Engelhardt KR, Gertz ME, Keles S, Schäffer AA, Sigmund EC, Glocker C, 
et al. The extended clinical phenotype of 64 patients with dedicator of cyto-
kinesis 8 deficiency. J Allergy Clin Immunol (2015) 136:402–12. doi:10.1016/ 
j.jaci.2014.12.1945 
4. Al-Herz W, Chu JI, van der Spek J, Raghupathy R, Massaad MJ, Keles S, 
et al. Hematopoietic stem cell transplantation outcomes for 11 patients with 
dedicator of cytokinesis 8 deficiency. J Allergy Clin Immunol (2016) 138:852–9. 
doi:10.1016/j.jaci.2016.02.022 
5. Cuellar-Rodriguez J, Freeman AF, Grossman J, Su H, Parta M, Murdock 
H, et  al. Matched related and unrelated donor hematopoietic stem cell 
transplantation for DOCK8 deficiency. Biol Blood Marrow Transplant (2015) 
21:1037–45. doi:10.1016/j.bbmt.2015.01.022 
6. Su HC, Zhing H, Zhang Q. DOCK8 deficiency. Ann N Y Acad Sci (2011) 
1246:26–33. doi:10.1111/j.1749-6632.2011.06295.x 
7. Lambe T, Crawford G, Johnson AL, Crockford TL, Bouriez-Jones T, Smyth 
AM, et  al. DOCK8 is essential for T-cell survival and the maintenance of 
CD8(+) T-cell memory. Eur J Immunol (2011) 41:3423–35. doi:10.1002/
eji.201141759 
8. Mizesko MC, Banerjee PP, Monaco-Shawver L, Mace EM, Bernal WE, 
Sawalle-Belohradsky J, et  al. Defective actin accumulation impairs human 
natural killer cell function in patients with dedicator of cytokinesis 8 defi-
ciency. J Allergy Clin Immunol (2013) 131:840–8. doi:10.1016/j.jaci.2012. 
12.1568 
9. Randall KL, Lambe T, Johnson A, Treanor B, Kucharska E, Domaschenz 
H, et al. Dock8 mutations cripple B cell immunological synapses, germinal 
centers and long-lived antibody production. Nat Immunol (2009) 10:1283–91. 
doi:10.1038/ni.1820 
10. Zhang Q, Dove CG, Hor JL, Murdock HM, Strauss-Albee DM, Garcia 
JA, et  al. DOCK8 regulates lymphocyte shape integrity for skin anti-
viral immunity. J Exp Med (2014) 211:2549–66. doi:10.1084/jem. 
20141307 
11. Roschewski M, Wilson WH. Lymphomatoid granulomatosis. Cancer J (2012) 
18:469–74. doi:10.1097/PPO.0b013e31826c5e19 
12. Jing H, Zhang Q, Zhang Y, Hill BJ, Dove CG, Gelfand EW, et  al. Somatic 
reversion in dedicator of cytokinesis 8 immunodeficiency modulates dis-
ease phenotype. J Allergy Clin Immunol (2014) 133:1667–75. doi:10.1016/ 
j.jaci.2014.03.025 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2017 Dimitriades, Devlin, Pittaluga, Su, Holland, Wilson, Dunleavy, 
Shah and Freeman. This is an open-access article distributed under the terms of the 
Creative Commons Attribution License (CC BY). The use, distribution or reproduc-
tion in other forums is permitted, provided the original author(s) or licensor are 
credited and that the original publication in this journal is cited, in accordance with 
accepted academic practice. No use, distribution or reproduction is permitted which 
does not comply with these terms.
